RE:RE:Avicanna financials released today Things looking upProblem with your 'analysis' is that you cannot see their purchase orders or 'order books' that starting driving the high growth numbers reported today. It's not a matter of 'cash' or 'burn rate', it's a matter of if AVCN wants to go it alone against other global pharma giants that already have distribution net works and shelf space in all major retailers. Sometimes it's better for a smaller company to join a larger company. The logic being....AVCN does not have anything that cannot be replicated or even made better by a large global pharma, look at LABS and their global pharma partner readying to launch a more effective generic version of Epidiolex.
Sure, it's new technology but in a very small way, w.r.t. to AVCN.